ENPP1 Gene: Function, Mutations, and Associated Diseases

ENPP1 encodes ectonucleotide pyrophosphatase/phosphodiesterase 1, a type II transmembrane glycoprotein that hydrolyzes extracellular nucleotides (e.g., ATP) to generate pyrophosphate (PPi). PPi is a critical inhibitor of hydroxyapatite crystal deposition, regulating bone mineralization and preventing ectopic calcification. ENPP1 is expressed in various tissues, including bone, cartilage, and vascular smooth muscle. Loss-of-function mutations cause generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemic rickets type 2 (ARHR2).

Tissue Expression

Cell Line Expression

Hotspot Mutations

Mutation functional classification

• Purine metabolism (Reactome R-HSA-74217)

• Pyrophosphate metabolism (Reactome R-HSA-8957275)

• Regulation of FGF23 production (Reactome R-HSA-8957275)

ENPP1 (PC-1) is a 925-amino acid type II transmembrane protein with an N-terminal cytoplasmic domain, a transmembrane helix, and a large extracellular domain containing the catalytic site. It hydrolyzes ATP to AMP and PPi, a key inhibitor of vascular and soft tissue calcification. The protein is expressed on the surface of various cells, including osteoblasts, chondrocytes, and vascular smooth muscle cells. Mutations impairing ENPP1 function lead to PPi deficiency, causing severe arterial calcification in infancy and hypophosphatemic rickets. The protein also interacts with insulin receptor signaling, linking it to metabolic functions.